Print this article

Life sciences M&As in the fourth quarter of 2018: notes, trends and a closer look at APAC

corresponding

ELISABET CRUCES
Clarivate Analytics, Barcelona, Spain

Abstract

During the fourth quarter of 2018, Cortellis Deals Intelligence, from Clarivate Analytics, tracked 140 new biopharma mergers and acquisitions (M&A) with a total disclosed deal value of $33.1 billion as part of its ongoing coverage of M&A activity in the life sciences sector. This compared to 153 and $20.3 billion in the third quarter and 151 and $100.7 billion in the fourth quarter of 2017. The transactions included 30 high-value new M&As accounted in Q4 2018  worth in excess of $100 million with 12 worth more than $500 million.


INTRODUCTION

During the fourth quarter of 2018, Cortellis Deals Intelligence registered 140 new mergers and acquisitions (M&A) with a total disclosed deal value of $33.1 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 153 and $20.3 billion in the third quarter and 151 and $100.7 billion in the fourth quarter of 2017 (See Figure 1).

The highest transaction for the period was the $5.7 billion offer done by Veritas Capital and Elliott Management for cloud-computing firm athenahealth, although its value fell well below the top M&A transactions, such as the $160 billion unsuccessful Pfizer bid for Allergan (which might have been history’s biggest pharma merger), the $69 billion CVS/Aetna combination, announced in the fourth quarter of 2015 and 2017, respectively, or the $74 billion offer of Bristol-Myers Squibb (BMS) by Celgene recently announced in 2019.


HIGH-VALUE M&AS WORTH $0.5B OR MORE

We tracked 30 high-value new M&As worth in excess of $100 million during the fourth quarter of 2018 with 12 worth mo ...



 

Teknoscienze publisher & event organiser
viale Brianza 22, 20127
Milano – Italy
info@teknoscienze.com
Tel +39 02 26809375

 

 

Subscribe now